![Craig Gibbs](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Craig Gibbs
Director Ejecutivo en Asher Biotherapeutics, Inc. .
Perfil
Craig S.
Gibbs is currently the Chief Executive Officer at Asher Biotherapeutics, Inc. He previously worked as the Chief Business Officer at Forty Seven, Inc. from 2015 to 2020.
Gibbs was also a VP-Commercial Strategy, Planning & Operations at Gilead Sciences, Inc. from 1992 to 2013.
He served as an Independent Director at Tobira Therapeutics, Inc. from 2014 to 2016 and at Aridis Pharmaceuticals, Inc. from 2015 to 2023.
Gibbs holds a doctorate from the University of Glasgow, an MBA from Golden Gate University, and an undergraduate degree from Massey University.
Cargos activos de Craig Gibbs
Empresas | Cargo | Inicio |
---|---|---|
Asher Biotherapeutics, Inc.
![]() Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Director Ejecutivo | 01/09/2020 |
Antiguos cargos conocidos de Craig Gibbs.
Empresas | Cargo | Fin |
---|---|---|
ARIDIS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 27/03/2023 |
FORTY SEVEN, INC. | Corporate Officer/Principal | 01/07/2020 |
Tobira Therapeutics, Inc. /Old/
![]() Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director/Miembro de la Junta | 01/09/2016 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2013 |
Formación de Craig Gibbs.
University of Glasgow | Doctorate Degree |
Golden Gate University | Masters Business Admin |
Massey University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
ARIDIS PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Tobira Therapeutics, Inc. /Old/
![]() Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Forty Seven, Inc.
![]() Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Asher Biotherapeutics, Inc.
![]() Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Commercial Services |
- Bolsa de valores
- Insiders
- Craig Gibbs